Clinical Trials Logo

Filter by:
NCT ID: NCT05689177 Enrolling by invitation - Humoral Immunity Clinical Trials

Humoral Immunity Study After Booster Vaccination of "Soberana Plus" (The Republic of Cuba) Against COVID-19

Start date: December 9, 2022
Phase: N/A
Study type: Interventional

To evaluate the dynamics of IgG levels to the SARS-CoV-2 virus after a booster dose of Soberana Plus vaccine.

NCT ID: NCT05535803 Enrolling by invitation - Tracheal Stenosis Clinical Trials

Treatment of Laryngotracheal Stenosis Using Mesenchymal Stem Cells

Start date: June 1, 2021
Phase: Phase 2
Study type: Interventional

The trial evaluates the safety and efficacy of the olfactory mucosa-derived mesenchymal stem cells based therapy for the patients with chronic laryngeal and tracheal stenosis

NCT ID: NCT05520125 Not yet recruiting - Clinical trials for Segmental Fracture - Bone Loss

Treatment of Patients With Bone Tissue Defects Using Mesenchymal Stem Cells Enriched by Extracellular Vesicles

Start date: November 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Treatment of patients with segmental bone tissue defects using mesenchymal stem cells enriched by extracellular vesicles

NCT ID: NCT05520112 Not yet recruiting - Clinical trials for Recurrent Pregnancy Loss

Treatment of Recurrent Pregnancy Loss Using Mesenchymal Stem Cells

Start date: November 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Treatment of Recurrent pregnancy loss using mesenchymal stem cells capable of differentiation in the endometrial-decidual direction.

NCT ID: NCT05335213 Recruiting - Liver Cirrhosis Clinical Trials

Urinary Tract Infections in Cirrhosis

Start date: January 5, 2022
Phase:
Study type: Observational [Patient Registry]

Evaluate the prevalence and types of urinary tract infections, the features of the gut and urinary tract microbiota in cirrhosis, to assess its importance in the development of complications and outcomes of cirrhosis.

NCT ID: NCT05334693 Recruiting - Clinical trials for Acute Myeloid Leukemia

Expanded Haploidentical Natural Killer Cells as Consolidation Strategy for Children/Young Adults With AML

Start date: November 1, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to estimate the efficacy of immunotherapy with ex vivo expanded haploidentical NK cells as consolidation therapy for children/young adults with intermediate risk AML.

NCT ID: NCT05333302 Recruiting - Clinical trials for B-cell Acute Lymphoblastic Leukemia

Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma

Start date: October 26, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to estimate the safety and the efficacy of CAR- T cells immunotherapy for children/young adults with relapsed or refractory acute lymphoblastic leukemia/lymphoma.

NCT ID: NCT05306119 Active, not recruiting - Low Back Pain Clinical Trials

Developing a Method of Rehabilitation for Patients After Myocardial Revascularization

Start date: July 1, 2021
Phase: N/A
Study type: Interventional

As a result, will be developed: a list of criteria for functional impairment in patients after myocardial revascularization combined with low back pain; a list of criteria for disabilities in patients after myocardial revascularization combined with low back pain; method of medical rehabilitation of patients after myocardial revascularization combined with low back pain; and criteria for evaluating its effectiveness.

NCT ID: NCT05272293 Recruiting - Clinical trials for Acute Myeloid Leukemia

Immunotherapy With ex Vivo Expanded Haploidentical Natural Killer Cells for Children/Young Adults With AML

Start date: November 1, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to estimate the efficacy of immunotherapy with ex vivo expanded haploidentical NK cells for children/young adults with primary high risk or refractory AML and relapsed AML.

NCT ID: NCT05269004 Recruiting - Multiple Sclerosis Clinical Trials

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

OLERO
Start date: May 3, 2022
Phase: Phase 3
Study type: Interventional

This is a Phase IIIb, single-arm, multicenter, OLE study. Participants receiving ocrelizumab as an investigational medicinal product (IMP) in a Roche sponsored Parent study who continue to receive ocrelizumab or are in safety follow-up at the time of the closure of their respective Parent study (WA21092, WA21093 or WA25046) are eligible for enrollment in this extension study. Participants who will continue ocrelizumab treatment will receive IMP based on the dosage and administration received at the time of rollover from the Parent study.